# Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial

> **Newsylist Open Intelligence Dossier** · First detected: 2026-07-30 04:29 UTC · Category: Business · Sources: 5 · Current Velocity: 2.8

## Executive Summary
5 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

## Intelligence Brief
"Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by Newsylist so far.


Outlets currently covering the story include Yahoo Finance, Fierce Biotech, Reuters and STAT. Newsylist measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.

## Verified Facts & Key Claims
### Why is "Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystroph" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst Newsylist classifies as a trend.

### How does Newsylist measure this trend?
Newsylist scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.

### Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.

## Key People, Organizations & Locations
FDA, Duchenne, Deramiocel, HOPE-3, Capricor's Duchenne, DMD Therapy Gets Lancet Backing Ahead Of August FDA Showdown

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| Yahoo Finance | Capricor’s DMD Therapy Gets Lancet Backing Ahead Of August FDA Showdown | 2026-07-29 14:03 | [Source Link](https://news.google.com/rss/articles/CBMimAFBVV95cUxQOXVQOXJldXhBLUVYZUhtRkhQd0hrWThQcEJGT3RlWDdfQUYxY1V6RmprN2xHYzhqVXhHSkNPMFdOd1ZoNGRTX1ozYTBXRmk2R0Z1b1pnS3BYSW9BVU9nWlk1RXJwVmMzTEd1OGRoVnE0VUVJa29ZLTRoVkJwNlRXZVY4b0FXWlpKTnJfZmVJdkdKLXYwWk5ndA?oc=5) |
| Fierce Biotech | FDA adcomm shoots down Capricor's Duchenne cell therapy after meeting marked by statistical dispute | 2026-07-29 14:03 | [Source Link](https://news.google.com/rss/articles/CBMiwwFBVV95cUxPc2FOcVE0cThtM1ZNbjVReF84ZFFyS3ZRT1pqUmpYbDZudUZzc0xtQzlRN0Eyb01BQV9jZWp2OEV1R19CSVl2ZVBVeXFWX0xHODVQeDJ3ZFBnNjlnc3dON0h6V0FNYjByN3hLV0pRLXhNbnJ2V0tTMUMweFJfMVpiRmFtTUR0NlVDMEhrR3RwUUJTZ2dWM1A3ekVkZGJtU3dnb0hBUkYyLXZLNmtNVm9nTE9iZ0swazNkOExyWXV3Qk5IdTA?oc=5) |
| Reuters | FDA panel votes against Capricor's Duchenne heart disease therapy | 2026-07-29 14:03 | [Source Link](https://news.google.com/rss/articles/CBMi0gFBVV95cUxOak9HZVhUZnY3QmJXSGtDZ0JCdlZ5Q3dWLU9ZYzAyV2pEWFBkREI2aTU5ZnliYkFJay1HNElhbWltSlZBNUtqMFVqMi0wMkdwU0tKQlRYS3NKRDEtd2xXTGFDRkxvaHVYWHFuMFlmVS0zRGNZRXlZRzNOM3llc2NudmNBTFRkcFhNblVxZldJQjNwaUVqLTdESE82WFkyMUJFZzltVENWUlpVcEhOZ0NjaXB1dWFjeWpPUml5YnVRSzROUTFOcVBzTnpBWU5HVEJkbGc?oc=5) |
| STAT | FDA expert panel recommends against approval of Capricor’s Duchenne drug | 2026-07-29 14:03 | [Source Link](https://news.google.com/rss/articles/CBMinwFBVV95cUxPejh6VERYRXZaZWc1RmFCNDloTXJnRWVKSWNVbkQyM2o1TS1YS0lXcWFwMDBJOHd3NGtUSjJHUlNOd2MwdWdZTEl4SmNVVWtEZDA5WTIwZlphcjFFS29NcjEwMVptVWxmX01UbFBZWlY1cktDV1ZRT3NFMld1Vy0tZ3pqcVR5U0FOWDdaRjRwNGM4T1h4TjhXY3BLYnFEZGs?oc=5) |
| The Lancet | Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial | 2026-07-29 14:03 | [Source Link](https://news.google.com/rss/articles/CBMiiwFBVV95cUxQRFBPNk9scTBmcFhhS3QzbEt2VkdNZHVQUWxoV2dFbVprRHRzQjQtTERheTNIZWVabWxEd3Byekx0TGw0dUlhaWxZT1lSSEJqdlRBVEk0amNVZXA0bzQzSXIyWnJXZkJ5dU1Fckp2T00yMTM0RlNjSkpFMzFXekZlTWg0WXBSVGZ4Vko4?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-07-30/deramiocel-heart-derived-cellular-therapy-in-advanced-duchenne-muscular*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*